Barinthus Biotherapeutics Future Growth
Future criteria checks 0/6
Barinthus Biotherapeutics's earnings are forecast to decline at 12.6% per annum while its annual revenue is expected to grow at 16.7% per year. EPS is expected to decline by 12.8% per annum. Return on equity is forecast to be -129.4% in 3 years.
Key information
-12.6%
Earnings growth rate
-12.8%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 16.7% |
| Future return on equity | -129.4% |
| Analyst coverage | Low |
| Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | -126 | N/A | -85 | 4 |
| 12/31/2025 | N/A | -124 | N/A | -123 | 3 |
| 12/31/2024 | N/A | -100 | N/A | -103 | 4 |
| 12/31/2023 | 1 | -73 | -56 | -51 | N/A |
| 9/30/2023 | 7 | -77 | -49 | -43 | N/A |
| 6/30/2023 | 13 | -55 | -28 | -20 | N/A |
| 3/31/2023 | 30 | -15 | -19 | -11 | N/A |
| 12/31/2022 | 45 | 5 | -21 | -14 | N/A |
| 9/30/2022 | 38 | 11 | -17 | -11 | N/A |
| 6/30/2022 | 32 | -1 | -29 | -25 | N/A |
| 3/31/2022 | 15 | -33 | -33 | -31 | N/A |
| 12/31/2021 | 0 | -51 | -34 | -33 | N/A |
| 9/30/2021 | 1 | -46 | -30 | -30 | N/A |
| 6/30/2021 | 4 | -41 | -29 | -28 | N/A |
| 3/31/2021 | 4 | -29 | -15 | -15 | N/A |
| 12/31/2020 | 5 | -18 | -11 | -11 | N/A |
| 12/31/2019 | 7 | -21 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BRNS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BRNS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BRNS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BRNS is forecast to have no revenue next year.
High Growth Revenue: BRNS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BRNS is forecast to be unprofitable in 3 years.